A detailed history of New Edge Advisors, LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, New Edge Advisors, LLC holds 209 shares of ACAD stock, worth $3,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares
209
Previous 209 -0.0%
Holding current value
$3,091
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$20.78 - $31.77 $2,265 - $3,462
109 Added 109.0%
209 $6,000
Q3 2023

Nov 14, 2023

SELL
$20.84 - $33.47 $2,084 - $3,347
-100 Reduced 50.0%
100 $2,000
Q1 2023

May 12, 2023

SELL
$16.32 - $20.92 $3,410 - $4,372
-209 Reduced 51.1%
200 $3,000
Q4 2022

Feb 14, 2023

BUY
$14.2 - $18.63 $5,807 - $7,619
409 New
409 $6,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.